Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cadherin 12 pseudogene 2 (CDH12P2) is one of several non-functional genomic elements derived from the parental Cadherin 12 gene, a type II classical cadherin expressed predominantly in the brain and involved in cell-cell adhesion during neuronal development[1][7]. Pseudogenes like CDH12P2 may not encode functional proteins but can regulate gene expression by acting as competitive endogenous RNAs (ceRNAs) or miRNA sponges—modulating processes such as cancer progression and epithelial-to-mesenchymal transition (EMT)[2]. CDH12P2 is located in the 5q13.2 region, potentially influencing genome stability and has been implicated, though not confirmed, in conditions like spinal muscular atrophy (SMA) due to locus effects[2]. There is no evidence for direct drug targeting, therapeutic intervention, or specific safety concerns tied to CDH12P2[5][2].
Not applicable. No drugs directly target this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin 12 pseudogene 2 (CDH12P2).